NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Lumexa Imaging Holdings LMRI

Lumexa Imaging Holdings listed on Nasdaq on 12 Dec 2025 and is not in the S&P 500. It is worth $1.4 billion. Its price history starts on 12 Dec 2025. Its board has 9 directors, 6 of them independent. 3 other officers are on file. At 30 Jun 2026, Brown Advisory was its largest institutional holder, with 6.0% of the company.

CEO
Caitlin Zulla
Chair
Henry Lee Cooper
Listed
12 Dec 2025 on Nasdaq, IPO filings and terms
Headquarters
Raleigh, NC
Market cap
$1.4B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Lumexa Imaging Holdings' quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2026

$0$100M$200M$300M20252026$272M

Revenue breakdown

Lumexa Imaging Holdings' $272M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.

Quarter to Sep 2026

  • Outpatient$202M, 74.3%
  • Professional$74M, 27.3%
  • Intersegment Eliminations-$4M, -1.5%

Lumexa Imaging Holdings' market cap since December 2025

Weekly, up to 13 Nov 2026

Jan 2026MarMayJulSepNov$1.4B

Board and leadership

Board and officers

3 people here also hold roles at other S&P 500 companies.

Board from the proxy filed 28 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (9)
Henry Lee CooperChairNot independent 路 since 2025Chief Executive Officer, AssistRx, LLCChair2025No63
Caitlin ZullaChief Executive OfficerNot independent 路 since 2025Other boards: National Vision HoldingsChief Executive Officer2025No48
Brett BrodnaxDirectorIndependent 路 since 2025 路 Compensation (chair), Nominating and Corporate Governance, Patient Safety and Quality of CareExecutive Chairman, United Surgical Partners International, Inc.Director2025YesCompensation (chair), Nominating and Corporate Governance, Patient Safety and Quality of Care61
Glenn A. EisenbergDirectorIndependent 路 since 2025 路 Audit (chair), CompensationSpecial Advisor, Labcorp Holdings Inc.Also at SolventumOther boards: Middleby and MiniMed GroupDirector2025YesAudit (chair), Compensation64
Molly JosephLead Independent DirectorIndependent 路 since 2025 路 Audit, Nominating and Corporate Governance (chair)Managing Partner, Cypress Pass Ventures, LLCAlso at West Pharmaceutical ServicesLead Independent Director2025YesAudit, Nominating and Corporate Governance (chair)52
Bridget E. KarlinDirectorIndependent 路 since 2025 路 Audit, Technology (chair)Managing Director, BEK Strategies, Inc.Also at LyondellBasellOther boards: DanaDirector2025YesAudit, Technology (chair)69
Matthew LungrenDirectorIndependent 路 since 2025 路 Patient Safety and Quality of Care (chair), TechnologyAdjunct Professor at Stanford and Clinical Associate Professor and practicing interventional radiologist at UCSFDirector2025YesPatient Safety and Quality of Care (chair), Technology48
Robert Louis Mittl Jr.DirectorNot independent 路 since 2025 路 Patient Safety and Quality of Care, TechnologyPracticing neuroradiologistDirector2025NoPatient Safety and Quality of Care, Technology66
Brian Thomas ReganDirectorIndependent 路 since 2025 路 Compensation, Nominating and Corporate GovernanceGeneral Partner, Welsh, Carson, Anderson & StoweDirector2025YesCompensation, Nominating and Corporate Governance48
Officers (3)
James Anthony MartinChief Financial OfficerLast filed 15 Jan 2026Chief Financial Officer
Russell StewartChief Medical OfficerLast filed 16 Dec 2025Chief Medical Officer
James Edward Walker Jr.Principal Accounting OfficerLast filed 27 Feb 2026Principal Accounting Officer

Owners and trading

Largest institutional holders

Each fund group's share of Lumexa Imaging Holdings. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 16.0% of Lumexa Imaging Holdings.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $476,950 in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
19 May 2026BuyBrett BrodnaxDirectorDirectorBuy35,000$254K
14 May 2026BuyHenry Lee CooperChairChairBuy30,000$223K

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 4 appointments of directors and officers in the last two years.

Left the company or board 1Appointed 4WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.